For patients with established cardiovascular disease, medications with proven cardiovascular benefit should be prioritized per ADA guidelines
This decision depends on individual health status, goals achieved, habits established, and presence of obesity-related conditions
Semaglutide uses a C18 fatty diacid, and tirzepatide uses a C20 fatty diacid structurally similar to retatrutide's approach
During your consultation be sure to share as much information as possible about your unique health history, family history, current medications, and known health conditions and allergies to find out if you are a good candidate for these medications, or if there are any concerns regarding complications
Similarly, another study found that overweight or obese adults who completed a 20-week run-in period and continued their treatment with semaglutide experienced ongoing weight loss as compared to those who took placebo [3]